SCHEMBL5388607

SCHEMBL5388607

c1ccc(CSc2nsc(OCc3cncnc3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ALOX15 P16050 2/20 0.52
HSD17B10 Q99714 1/20 0.43
PLA2G7 Q13093 5/20 0.40
NPC1 O15118 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 3/20 0.38
CXCR2 P25025 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 2/20 0.36
PKM P14618 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PAK4 O96013 1/20 0.36
HSP90AA1 P07900 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5378195 0.90 RAB9A (0.59) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL5372995 0.83 ALOX15 (0.51) RAB9ASMN1; SMN2ALOX15HSD17B10TDP1
SCHEMBL5381470 0.83 RAB9A (0.48) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL5388491 0.81 CTSB (0.50) RAB9ASMN1; SMN2ALOX15NPC1TDP1
SCHEMBL4800890 0.81 RAB9A (0.49) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL5387247 0.79 MAPK1 (0.35) RAB9ASMN1; SMN2HSD17B10TDP1ALDH1A1
SCHEMBL5422577 0.77 SMN1; SMN2 (0.42) RAB9ASMN1; SMN2ALOX15HSD17B10L3MBTL1
SCHEMBL5375842 0.75 L3MBTL1 (0.44) RAB9ASMN1; SMN2ALOX15NPC1ALDH1A1
SCHEMBL5377736 0.75 LMNA (0.47) RAB9ASMN1; SMN2ALOX15HSD17B10TDP1
SCHEMBL5427209 0.74 SMN1; SMN2 (0.40) RAB9ASMN1; SMN2ALOX15TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 US disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH RAB9A 1998/4885SMN1; SMN2 3880/4885ALOX15 940/4885
US-20070293510-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH RAB9A 2211/4885SMN1; SMN2 3891/4885ALOX15 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.